Giuseppe Lamberti

44PUBLICATIONS
252CO-AUTHORS
Predictive and prognostic markersDisease surveillanceSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Feb 16, 2026
Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis.

Giuseppe Lamberti, Francesco Panzuto, Maria Rinzivillo

|Feb 04, 2026
Determinants of incidence trends in pancreatic neuroendocrine neoplasms.

Giuseppe Lamberti, Elisa Andrini, Adriana Di Odoardo

|Aug 28, 2025
Updates on Pulmonary Neuroendocrine Carcinoids: Progress and Perspectives.

Anna Scognamiglio, Arianna Zappi, Elisa Andrini

|May 09, 2025
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.

Giuseppe Lamberti, Karim Rihawi, Francesca Mazzoni

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

|Jan 24, 2025
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids.

Linda Galvani, Arianna Zappi, Sara Pusceddu

Pageof 8

Frequent Collaborators

16 joint publications

Davide Campana

11 joint publications

Biagio Ricciuti

8 joint publications

Mark M Awad

8 joint publications

Joao Victor Alessi